<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946658</url>
  </required_header>
  <id_info>
    <org_study_id>RGV-GARM 2</org_study_id>
    <nct_id>NCT02946658</nct_id>
  </id_info>
  <brief_title>Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders</brief_title>
  <acronym>ADcSVF-COPD</acronym>
  <official_title>Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Chronic Lung Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healeon Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry, Glenn C., M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Healeon Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized&#xD;
      by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen&#xD;
      tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and&#xD;
      interference with oxygen-carbon dioxide exchange.&#xD;
&#xD;
      Air pollution and tobacco smoking are felt to be the most common cause of these issues.&#xD;
      Diagnostic testing is based on poor airflow measured by lung function studies and whose&#xD;
      symptoms do not improve much with antiasthma bronchodilators.&#xD;
&#xD;
      Study is an interventional study to document the safety and efficacy of use of AD-cSVF in&#xD;
      chronic broncho-pulmonary disease groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD is often treated by limiting exposure to poor air quality, but there is no cure at this&#xD;
      time. Attempted therapy include smoking cessation, vaccinations, respiratory rehabilitation,&#xD;
      and attempts of use of bronchodilators and steroids. Many resort to supplemental oxygen&#xD;
      therapy, lung transplantation, and antibiotic supportive therapy during exacerbations.&#xD;
&#xD;
      As of 2013, COPD involve approximately 5% pf the global populations (approximately 330&#xD;
      million). Most commonly it occurs approximately equally between men/women and result in about&#xD;
      3 million deaths per year. Estimates of economic costs are estimated to be more than 2.1&#xD;
      trillion dollars in 2010.&#xD;
&#xD;
      This study includes microcannula harvesting of subdermal adipose tissues, incubation,&#xD;
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual&#xD;
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline&#xD;
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured&#xD;
      at intervals (both severe and non-severe categories) and by repeated pulmonary function&#xD;
      studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Pulmonary Function</measure>
    <time_frame>12 months Evaluate Function and Adverse Events</time_frame>
    <description>Pulmonary Function to be Addressed as occurrence or frequency of adverse event during study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Respiratory Rate</measure>
    <time_frame>1 month, 6 month, 1 year</time_frame>
    <description>Measured rate clinically at rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOLD Classification</measure>
    <time_frame>1 year</time_frame>
    <description>Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a COPD staging system based on degree of airflow limitations (obstruction) and measured by pulmonary function studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 6 Minute Walk Test</measure>
    <time_frame>12 Months</time_frame>
    <description>Exercise capacity measured by distance a patient can walk in 6 minute timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Lung X-Ray</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>standard flat film x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline SGOT Blood Testing</measure>
    <time_frame>1 Month</time_frame>
    <description>Measure Blood Serum Glutamate Oxaloacetate Transaminase (SGOT) Measure Blood Elevation with liver damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline SGPT Blood Testing</measure>
    <time_frame>1 Month</time_frame>
    <description>Measure Blood Serum Glutamate Pyruvate Transaminase (SGPT) elevation with liver damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Measure Baseline Pulmonary Function (FEV/FEVi Measure)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline IV with AD-cSVF cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lipoaspiration</intervention_name>
    <description>Closed syringe harvesting subdermal fat</description>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADcSVF</intervention_name>
    <description>Isolation of AD-cSVF</description>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline IV</intervention_name>
    <description>Normal Saline IV containing AD-cSVF</description>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior Diagnosis of moderate to severe COPD&#xD;
&#xD;
          -  GOLD II a, III, IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or Lactating Females&#xD;
&#xD;
          -  Life expectancy of &lt; 3 months due to concomitant illnesses&#xD;
&#xD;
          -  Exposure to any investigational drug or procedure with 1 month prior to study entry or&#xD;
             enrollment in concurrent study which may interfere with interpretation of study&#xD;
             results&#xD;
&#xD;
          -  Illness which, in investigators judgement, may interfere with the patient' ability to&#xD;
             comply with protocol, compromise patient safety, ability to provide informed consent&#xD;
             to study, or interfere with interpretation of study outcomes&#xD;
&#xD;
          -  Subjects on chronic immunosuppressive or chemotherapeutic medications&#xD;
&#xD;
          -  Known drug or alcohol dependence or other factors which may interfere with study&#xD;
             conduct or interpretation of result or in the opinion of investigator are not suitable&#xD;
             to participate.&#xD;
&#xD;
          -  Subjects with documented Alpha-1 Antitrypsin Deficiency (Inherited lung and liver&#xD;
             disorder)&#xD;
&#xD;
          -  Unwilling or not competent to understand and execute an informed consent agreement&#xD;
&#xD;
          -  Patients positive for Hepatitis (Hepatitis A history excepted)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Alexander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Healeon Medical Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn C. Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Alliance for Regenerative Medicine (GARM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regenevita LLC</name>
      <address>
        <city>Stevensville</city>
        <state>Montana</state>
        <zip>59870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Alliance for Regenerative Medicine (GARM)</name>
      <address>
        <city>Roatan</city>
        <state>HN</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012 Apr 7;379(9823):1341-51. doi: 10.1016/S0140-6736(11)60968-9. Epub 2012 Feb 6. Review.</citation>
    <PMID>22314182</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.</citation>
    <PMID>17507545</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442.</citation>
    <PMID>17132052</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 May;3(3):234-8. Review.</citation>
    <PMID>16636091</PMID>
  </results_reference>
  <results_reference>
    <citation>Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008250. doi: 10.1002/14651858.CD008250.pub2. Review.</citation>
    <PMID>23076942</PMID>
  </results_reference>
  <results_reference>
    <citation>Kennedy SM, Chambers R, Du W, Dimich-Ward H. Environmental and occupational exposures: do they affect chronic obstructive pulmonary disease differently in women and men? Proc Am Thorac Soc. 2007 Dec;4(8):692-4. Review.</citation>
    <PMID>18073405</PMID>
  </results_reference>
  <results_reference>
    <citation>Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ. 2006 May 13;332(7550):1142-4. Review.</citation>
    <PMID>16690673</PMID>
  </results_reference>
  <results_reference>
    <citation>Foreman MG, Campos M, Celedón JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am. 2012 Jul;96(4):699-711. doi: 10.1016/j.mcna.2012.02.006. Epub 2012 Mar 6. Review.</citation>
    <PMID>22793939</PMID>
  </results_reference>
  <results_reference>
    <citation>Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ. 2012 Sep 4;184(12):1365-71. doi: 10.1503/cmaj.111749. Epub 2012 Jul 3. Review.</citation>
    <PMID>22761482</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Apr;3(2):180-4. Review.</citation>
    <PMID>16565429</PMID>
  </results_reference>
  <results_reference>
    <citation>Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Med Clin North Am. 2012 Jul;96(4):789-809. doi: 10.1016/j.mcna.2012.02.008. Epub 2012 Mar 16. Review.</citation>
    <PMID>22793945</PMID>
  </results_reference>
  <results_reference>
    <citation>Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD005305. doi: 10.1002/14651858.CD005305.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 08;12 :CD005305.</citation>
    <PMID>21975749</PMID>
  </results_reference>
  <results_reference>
    <citation>Saxena A, Watkin SW. Bilateral malignant testicular carcinoid. Br J Urol. 1990 Mar;65(3):302-3.</citation>
    <PMID>2337756</PMID>
  </results_reference>
  <results_reference>
    <citation>Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. Review.</citation>
    <PMID>24615270</PMID>
  </results_reference>
  <results_reference>
    <citation>COPD Working Group. Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12(7):1-64. Epub 2012 Mar 1. Review.</citation>
    <PMID>23074435</PMID>
  </results_reference>
  <results_reference>
    <citation>Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004356. Review.</citation>
    <PMID>16235359</PMID>
  </results_reference>
  <results_reference>
    <citation>Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010257. doi: 10.1002/14651858.CD010257. Review. Update in: Cochrane Database Syst Rev. 2018 Oct 29;10:CD010257.</citation>
    <PMID>23235687</PMID>
  </results_reference>
  <results_reference>
    <citation>Inamdar AC, Inamdar AA. Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res. 2013 Oct;39(8):315-27. doi: 10.3109/01902148.2013.816803. Epub 2013 Aug 30. Review.</citation>
    <PMID>23992090</PMID>
  </results_reference>
  <results_reference>
    <citation>Conese M, Piro D, Carbone A, Castellani S, Di Gioia S. Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity. ScientificWorldJournal. 2014 Jan 19;2014:859817. doi: 10.1155/2014/859817. eCollection 2014. Review.</citation>
    <PMID>24563632</PMID>
  </results_reference>
  <results_reference>
    <citation>McQualter JL, Anthony D, Bozinovski S, Prêle CM, Laurent GJ. Harnessing the potential of lung stem cells for regenerative medicine. Int J Biochem Cell Biol. 2014 Nov;56:82-91. doi: 10.1016/j.biocel.2014.10.012. Epub 2014 Oct 15. Review.</citation>
    <PMID>25450456</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzouvelekis A, Ntolios P, Bouros D. Stem cell treatment for chronic lung diseases. Respiration. 2013;85(3):179-92. doi: 10.1159/000346525. Epub 2013 Jan 29. Review. Erratum in: Respiration. 2013;86(4):294.</citation>
    <PMID>23364286</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzouvelekis A, Laurent G, Bouros D. Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets. 2013 Feb;14(2):246-52. Review.</citation>
    <PMID>23256721</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healeon Medical Inc</investigator_affiliation>
    <investigator_full_name>Robert W. Alexander, MD, FICS</investigator_full_name>
    <investigator_title>Principal Investigator, Science</investigator_title>
  </responsible_party>
  <keyword>COPD, Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

